|

Alzheimer's Disease Clinical Trials in San Francisco, CA

31 recruiting studies within 50 miles

Phase
Trial Phase Dist.
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantPhase 3<1 mi
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy VolunteersPhase 1/2<1 mi
Longitudinal Early-onset Alzheimer's Disease Study Protocol—<1 mi
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in DementiaPhase 1/2<1 mi
Remotely-supervised Neuromodulation in PPAN/A<1 mi
[18F]PI-2620 Phase 3 Histopathological StudyPhase 3<1 mi
A Study of Psychedelics in Healthy Older Adults With Low Well-beingPhase 1<1 mi
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)Phase 2<1 mi
Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project—<1 mi
Alzheimer's Tau Platform: Master ProtocolPhase 2<1 mi
Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183AEarly 1<1 mi
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseasePhase 3<1 mi
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's DiseasePhase 28 mi
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseasePhase 38 mi
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease StudiesPhase 38 mi
Computerized Tests of Cognitive Decline in Presymptomatic Alzheimer's DiseaseN/A10 mi
Door-Through-Door Companion Rideshare Technology for Individuals With Alzheimer's Disease and Related Dementias (AD/ADRD)Phase 115 mi
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)Phase 321 mi
Senicapoc in Alzheimer's DiseasePhase 221 mi
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's DiseasePhase 221 mi
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)Phase 321 mi
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)Phase 321 mi
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)Phase 321 mi
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)Phase 321 mi
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).Phase 321 mi
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)Phase 228 mi
Robotic-Enabled Microsurgical Intervention for Neurodegenerative DiseaseN/A28 mi
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)Phase 328 mi
Bumetanide in Patients With Alzheimer's DiseasePhase 228 mi
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases—32 mi
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)Phase 337 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.